Filing Flows › Syndax Pharmaceuticals (SNDX) › Q4 2025
Syndax Pharmaceuticals (SNDX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Syndax Pharmaceuticals (SNDX) reported revenue of $68.7M for the fourth quarter 2025 (Q4 2025), +795% from a year earlier and +50% from the quarter before. Operating margin was -91.0%, net loss $68.0M (99.0% of revenue).
Syndax Pharmaceuticals, Q4 2025: revenue $68.7M (+795% year over year), operating margin -91.0%, net loss $68.0M, operating cash flow −$69.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $68.7M | +50% | +795% |
| Operating profit | −$62.5M | — | — |
| Net earnings | −$68.0M | — | — |
| Operating cash flow | −$69.5M | — | — |
What changed
Revenue was $68.7M in Q4 2025, up 795% year over year and up 50% from the previous quarter.
Operating costs exceeded revenue by $62.5M, an operating margin of -91.0%. Total costs grew 26% against revenue growth of 795%. The fastest-growing cost line was Other operating costs (+37%). The quarter ended with a net loss of $68.0M, wider than the previous quarter's $60.7M loss.
Operating cash flow was −$69.5M. Non-cash charges added back $3.0M of depreciation and $11.3M of share-based compensation. Working capital and other items used $15.7M.
Questions
What was Syndax Pharmaceuticals' revenue in the fourth quarter 2025?
Syndax Pharmaceuticals (SNDX) reported revenue of $68.7M for the fourth quarter 2025 (Q4 2025), +795% from a year earlier and +50% from the quarter before.
Was Syndax Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $62.5M (-91.0% of revenue) and net loss $68.0M.